Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Bullish +75

Bristol-Myers Squibb: Why I'm Still Bullish After Q2

AI-generated analysis

📈 BMY stock reached a 52-week high of $64.96 on June 28 following Q2 results.

💰 Q2 revenue totaled $12.97 billion, marking a 12.9% quarter-over-quarter increase.

🚀 Non-GAAP EPS jumped 39.7% year-over-year and 29.1% quarter-over-quarter to $2.04.

📊 The company raised its 2026 diluted EPS guidance from $6.05-$6.35 to $6.75-$7.

💉 Strong demand is driving sales for Opdivo Qvantig and Breyanzi products.

🔬 Iza-Bren shows promising efficacy in triple-negative breast cancer trials.

📝 The article asserts the current risk/reward profile for BMY remains attractive.

Bullish Signals
  • BMY stock hit a 52-week high of $64.96, indicating strong market confidence following Q2 results.
  • Revenue grew by 12.9% to $12.97 billion in the second quarter, demonstrating solid top-line growth.
  • Non-GAAP EPS increased significantly by 39.7% year-over-year and 29.1% quarter-over-quarter to $2.04.
  • The company raised its full-year 2026 diluted EPS guidance from $6.05-$6.35 to $6.75-$7, signaling improved profitability expectations.
  • Strong demand for Opdivo Qvantig and Breyanzi is providing a reliable revenue stream.
  • Promising clinical efficacy of Iza-Bren in triple-negative breast cancer suggests potential future value.
Full Analysis
Bristol-Myers Squibb (BMY) concluded the second quarter with a strong performance, driving its stock price to a 52-week high of $64.96 on June 28. The company reported Q2 revenue of $12.97 billion, representing a 12.9% increase quarter-over-quarter. Non-GAAP earnings per share surged 39.7% year-over-year and 29.1% quarter-over-quarter to reach $2.04, significantly beating the author's base case scenario. Following the earnings release, Bristol-Myers Squibb raised its full-year 2026 diluted EPS guidance from a previous range of $6.05-$6.35 to a new target of $6.75-$7. The rally is attributed to promising efficacy data for Iza-Bren in triple-negative breast cancer and sustained strong demand for key products Opdivo Qvantig and Breyanzi. The article concludes that the stock's risk/reward profile remains attractive despite recent gains. The author, representing Allka Research, highlights the conservative investment approach and substantial returns associated with the company within the pharmaceutical sector. While the text includes standard disclosures regarding a beneficial long position in LEGN and general Seeking Alpha disclaimers, the core financial narrative focuses on BMY's robust earnings beat and upward revision of profit expectations.